In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8⁺ T cell responses
J. Clin. Invest. Christoph Esslinger, et al. 111:1673 doi:10.1172/JCI17098 [Go to this article.]

Figure 5
Recall immunizations with miniMelan-A lentivector 60 days after primary immunization with either miniMelan-A lentivector or an irrelevant lentivector. Indicated is the proportion of Melan-A–specific CD8⁺ cells obtained at the peak of recall response of all individual mice tested (dashed lines indicate the average levels of ELA_26–35-specific cells present before recall immunization).